Form 4: Corcept Officer Sells Shares After Option Exercise

Corcept Therapeutics' Chief Accounting & Technology Officer, Joseph Douglas Lyon, exercised stock options and subsequently sold a portion of his common stock holdings under a pre-arranged 10b5-1 plan.

Summary

• Joseph Douglas Lyon, Chief Accounting & Technology Officer of Corcept Therapeutics Inc. (CORT), reported transactions on October 1, 2025.
• Exercised 5,000 stock options at an exercise price of $13.56 per share.
• Subsequently sold a total of 5,000 shares of common stock in multiple transactions.
• The sales were executed under a Rule 10b5-1 trading plan adopted on August 30, 2024.
• Shares were sold at weighted average prices of $83.7111 (927 shares), $84.9217 (3,473 shares), and $85.3875 (600 shares).
• Following these transactions, direct beneficial ownership of common stock is 10,277 shares.
• Holds 21,571 derivative securities (stock options) after the reported transactions.
• Common stock holdings include 1,380 shares underlying unvested restricted stock awards, which vest on the one-year anniversary of their respective grant dates.

Sentiment

Score: 5

Explanation: The sentiment is neutral as this is a routine, pre-planned insider transaction (10b5-1 plan) involving both option exercise and subsequent share sales, which does not inherently signal strong positive or negative company-specific news.

Positives

• Officer exercised options, indicating a belief in the company's value at the exercise price.
• Sales were made at significantly higher prices than the exercise price, realizing a substantial gain for the officer.
• Transactions were conducted under a pre-arranged 10b5-1 plan, suggesting the sales were not based on new, non-public information.

Negatives

• Officer sold a significant number of shares (5,000 shares), reducing direct common stock ownership.

Risks

• General market risk associated with holding equity.

Future Outlook

The filing does not contain any forward-looking statements or guidance regarding the company's future performance or strategic direction.

Industry Context

This is a routine insider transaction report and does not provide specific context on broader industry trends or competitive landscape for Corcept Therapeutics.

Corporate Governance

Stakeholder Impact

• Shareholders: The transaction is a routine insider sale under a pre-arranged plan and is unlikely to have a significant direct impact on the company's operational or strategic outlook. It represents an executive monetizing vested equity.

Next Steps

• Vesting of remaining unvested restricted stock awards on their respective one-year anniversaries of the grant dates (December 2, 2024, March 3, 2025, June 2, 2025, and September 2, 2025).

Key Dates

Keywords

Corcept Therapeutics, CORT, Form 4, Insider Transaction, Stock Option Exercise, Share Sale, 10b5-1 Plan, Officer Transaction